Aldeyra Therapeutics, Inc. (ALDX)
0.9163
-0.03
(-3.31%)
USD |
NASDAQ |
Oct 09, 16:00
0.9283
+0.01
(+1.31%)
After-Hours: 20:00
Aldeyra Therapeutics Net Income (Quarterly) : -5.450M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.450M |
| March 31, 2026 | -3.453M |
| December 31, 2025 | -6.462M |
| September 30, 2025 | -7.688M |
| June 30, 2025 | -9.767M |
| March 31, 2025 | -9.930M |
| December 31, 2024 | -15.81M |
| September 30, 2024 | -15.11M |
| June 30, 2024 | -16.85M |
| March 31, 2024 | -8.082M |
| December 31, 2023 | -4.753M |
| September 30, 2023 | -8.187M |
| June 30, 2023 | -8.987M |
| March 31, 2023 | -15.62M |
| December 31, 2022 | -12.90M |
| September 30, 2022 | -14.55M |
| June 30, 2022 | -17.78M |
| March 31, 2022 | -16.79M |
| December 31, 2021 | -15.75M |
| September 30, 2021 | -15.80M |
| June 30, 2021 | -14.94M |
| March 31, 2021 | -11.29M |
| December 31, 2020 | -11.29M |
| September 30, 2020 | -8.873M |
| June 30, 2020 | -7.520M |
| Date | Value |
|---|---|
| March 31, 2020 | -9.868M |
| December 31, 2019 | -13.16M |
| September 30, 2019 | -18.72M |
| June 30, 2019 | -13.33M |
| March 31, 2019 | -15.62M |
| December 31, 2018 | -10.63M |
| September 30, 2018 | -10.81M |
| June 30, 2018 | -9.050M |
| March 31, 2018 | -8.397M |
| December 31, 2017 | -6.954M |
| September 30, 2017 | -4.986M |
| June 30, 2017 | -5.309M |
| March 31, 2017 | -5.091M |
| December 31, 2016 | -4.651M |
| September 30, 2016 | -4.775M |
| June 30, 2016 | -4.303M |
| March 31, 2016 | -4.967M |
| December 31, 2015 | -4.356M |
| September 30, 2015 | -3.366M |
| June 30, 2015 | -2.232M |
| March 31, 2015 | -2.137M |
| December 31, 2014 | -2.445M |
| September 30, 2014 | -2.009M |
| June 30, 2014 | -1.277M |
| March 31, 2014 | 0.2102M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.450M |
| EPS Diluted (Quarterly) | -0.0904 |
| Enterprise Value | 10.33M |
| Earnings Yield | -41.79% |
| Normalized Earnings Yield | -41.79 |